AZN's COVID-19 Vaccine Shows Strong Responses, ACAD Fails CLARITY Study, BTAI Hits New High

Today's Daily Dose brings you news about disappointing results from ACADIA's major depressive disorder drug trial, AstraZeneca's promising results of COVID-19 vaccine candidate, BioXcel Therapeutics' SERENITY program, Immuron's update on its new therapeutic against campylobacter and ETEC (E-Coli) and very encouraging results of Synairgen's SNG001 in hospitalized COVID-19 patients.

from RTT - Biotech https://ift.tt/2OKp0uQ
via IFTTT